HLS HLS Therapeutics Inc.
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders and cardiovascular disease in Canada, the United States, and internationally. The company offers Clozaril (clozapine tablets), an atypical antipsychotic to manage symptoms of treatment-resistant schizophrenia; CSAN Pronto device, which enhances and simplifies the mandatory safety blood monitoring process for patients that are prescribed Clozaril; Nilemdo, a bempedoic acid product for cardiovascular risk reduction; Nexlizet, a bempedoic acid and ezetimibe product for cardiovascular risk reduction; and Vascepa, an icosapent ethyl capsule for the treatment of cardiovascular disease. It also distributes MyCare psychiatry lab assays, which are a line of tests that can be processed on analyzers used in laboratory systems to measure the blood levels of the most common antipsychotic drugs, including clozapine, risperidone, quetiapine, aripiprazole, olanzapine, and paliperidone; and MyCare Insite, a point-of-care device that requires only a single drop of blood taken by a finger stick to measure patient drug levels. In addition, the company holds royalty interest in Takeda's Obizur, a porcine recombinant Factor VIII for acquired Hemophilia A. It serves wholesalers and institutions. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About HLS Therapeutics (TSE: HLS)
›
HLS Therapeutics (TSE: HLS) is listed on the Toronto Stock Exchange, where its shares trade in CAD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 85 employees.
The shares were at 3.670 CAD on 19 November 2026, down 31.0% over 52 weeks. Its 52-week range is 0.0010 CAD to 5.380 CAD: the price is 31.8% below the high and 366900.0% above the low.
Its market capitalisation is 113.53M CAD.
HLS Therapeutics reports return on equity of -20.2%, an operating margin of -8.0% and revenue up 3.5% year over year.
Its debt exceeds its cash by 28.17M USD, a debt-to-equity ratio of 0.81. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 4 analysts cover the stock, with an average rating of Buy; their mean price target of 7.379 CAD is 101.1% above the current price. The next earnings report is expected on 11 March 2027.